Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors

Contemporary Clinical Trials

Volumn 47, Issue , 2016, Pages 64-71

  Patterson, Ruth E ^a   Marinac, Catherine R ^a,b   Natarajan, Loki ^a   Hartman, Sheri J ^a   Cadmus Bertram, Lisa ^c   Flatt, Shirley W ^a   Li, Hongying ^a   Parker, Barbara ^a   Oratowski Coleman, Jesica ^a   Villaseñor, Adriana ^a   Godbole, Suneeta ^a   Kerr, Jacqueline ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Breast cancer; Metformin; Survivorship; Trial; Weight loss

Indexed keywords

BIOLOGICAL MARKER; METFORMIN; PLACEBO; SEX HORMONE; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; ESTRADIOL; INSULIN;

ADULT; ARTICLE; BREAST CANCER; CALORIC INTAKE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVOR; COMPARATIVE STUDY; CONTROLLED STUDY; COUNSELING; DISEASE ASSOCIATION; DRUG DOSE INCREASE; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; MORNING DOSAGE; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICAL ACTIVITY; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEDENTARY LIFESTYLE; SLEEP DISORDER; SLEEP QUALITY; SOCIAL COGNITIVE THEORY; TREATMENT DURATION; WEIGHT REDUCTION; ACTIVITY TRACKER; AGED; BREAST TUMOR; COMPLICATION; EXERCISE; GLUCOSE BLOOD LEVEL; METABOLISM; PATIENT SELECTION; PROCEDURES; SURVIVOR; TELEPHONE; VERY ELDERLY; WEIGHT LOSS PROGRAM;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BREAST NEOPLASMS; C-REACTIVE PROTEIN; ESTRADIOL; EXERCISE; FEMALE; FITNESS TRACKERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; PATIENT SELECTION; POSTMENOPAUSE; QUALITY OF LIFE; SURVIVORS; TELEPHONE; WEIGHT REDUCTION PROGRAMS;

EID: 84955279452     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.12.009     Document Type: Article

References (66)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2012 April 2015, National Cancer Institute, Bethesda, MD, (http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site).
2. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA Feb. 26 2014, 311(8):806-814.
3. Boyle J.P., Honeycutt A.A., Narayan K.M., et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care Nov. 2001, 24(11):1936-1940.
4. Erickson K., Patterson R.E., Flatt S.W., et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J. Clin. Oncol. Jan. 1 2011, 29(1):54-60.
5. Patterson R.E., Cadmus L.A., Emond J.A., Pierce J.P. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas May 2010, 66(1):5-15.
6. Luo J., Virnig B., Hendryx M., et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res. Treat. Nov. 2014, 148(1):153-162.
7. Joung K.H., Jeong J.W., Ku B.J. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. BioMed Res. Int. 2015, 2015:920618.
8. Vona-Davis L., Rose D.P. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr. Diabetes Rev. Mar. 2012, 8(2):116-130.
9. Mason C., Foster-Schubert K.E., Imayama I., et al. Dietary weight loss and exercise effects on insulin resistance in postmenopausal women. Am. J. Prev. Med. Oct 2011, 41(4):366-375.
10. Campbell K.L., Foster-Schubert K.E., Alfano C.M., et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J. Clin. Oncol. Jul. 1 2012, 30(19):2314-2326.
11. Rock C.L., Doyle C., Demark-Wahnefried W., et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J. Clin. Jul.-Aug. 2012, 62(4):243-274.
12. Irwin M.L., Fabian C., McTiernan A. Risk reduction from weight management and physical activity interventions. Adv. Exp. Med. Biol. 2015, 862:193-212.
13. Goodwin P.J., Ligibel J.A., Stambolic V. Metformin in breast cancer: time for action. J. Clin. Oncol. 2009, 27(20):3271-3273.
14. Niraula S., Dowling R.J., Ennis M., et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 2012, 135(3):821-830.
15. Guppy A., Jamal-Hanjani M., Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol. 2011, 7(6):727-736.
16. Goodwin P.J., Stambolic V., Lemieux J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat. 2011, 126(1):215-220.
17. Campagnoli C., Pasanisi P., Abba C., et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin. Breast Cancer 2012, 12(3):175-182.
18. Goodwin P.J., Stambolic V. Obesity and insulin resistance in breast cancer-chemoprevention strategies with a focus on metformin. Breast 2011, 20(Suppl. 3):S31-S35.
19. Lega I.C., Austin P.C., Gruneir A., Goodwin P.J., Rochon P.A., Lipscombe L.L. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013, 36(10):3018-3026.
20. A phase III randomized trial of metformin vs placebo in early stage breast cancer. (Accessed August 25, 2015). https://clinicaltrials.gov/ct2/show/NCT01101438.
21. Patterson R.E., Rock C.L., Kerr J., et al. Metabolism and breast cancer risk: frontiers in research and practice. J. Acad. Nutr. Diet. 2013, 113(2):288-296.
22. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4(8):579-591.
23. Schlienger J.L., Luca F., Vinzio S., Pradignac A. Obesity and cancer. La Revue de medecine interne/fondee. par la Societe nationale francaise de medecine interne 2009, 30(9):776-782.
24. Dwolatzky T., Whitehead V., Doniger G.M., et al. Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. 2003, 3:4.
25. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
26. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory 1986, Prentice Hall, Englewood Cliffs, NJ.
27. Wing R.R., Hamman R.F., Bray G.A., et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes. Res. 2004, 12(9):1426-1434.
28. (Accessed September, 3, 2015). https://www.myfitnesspal.com/.
29. U.S.Department of Agriculture, U.S.Department of Health and Human Services Dietary Guidelines for Americans. 7th ed. 2010, 2010. U.S. Governmenr Printing Office, Washington DC.
30. Janz K.F. Validation of the CSA accelerometer for assessing children's physical activity. Med. Sci. Sports Exerc. 1994, 26(3):369-375.
31. Melanson E.L., Freedson P.S. Validity of the Computer Science and Applications, Inc. (CSA) activity monitor. Med. Sci. Sports Exerc. 1995, 27(6):934-940.
32. Plasqui G., Westerterp K.R. Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity 2007, 15(10):2371-2379.
33. Choi L., Liu Z., Matthews C.E., Buchowski M.S. Validation of accelerometer wear and nonwear time classification algorithm. Med. Sci. Sports Exerc. 2011, 43(2):357-364.
34. Matthews C.E., Chen K.Y., Freedson P.S., et al. Amount of time spent in sedentary behaviors in the United States, 2003-2004. Am. J. Epidemiol. 2008, 167(7):875-881.
35. Freedson P.S., Melanson E., Sirard J. Calibration of the computer science and applications, Inc. accelerometer. Med. Sci. Sports Exerc. 1998, 30(5):777-781.
36. Armstrong T., Bull F. Development of the World Health Organization global physical activity questionnaire (GPAQ). J. Public Health 2006, 14:66-70.
37. Bull F.C., Maslin T.S., Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J. Phys. Act. Health 2009, 6(6):790-804.
38. Hoos T., Espinoza N., Marshall S., Arredondo E.M. Validity of the global physical activity questionnaire (GPAQ) in adult Latinas. J. Phys. Act. Health 2012, 9(5):698-705.
39. Rosenberg D.E., Norman G.J., Wagner N., Patrick K., Calfas K.J., Sallis J.F. Reliability and validity of the sedentary behavior questionnaire (SBQ) for adults. J. Phys. Act. Health 2010, 7(6):697-705.
40. Patient reported outcomes measurement information system (PROMIS). (Accessed August, 25, 2015). http://www.nihpromis.org/about/abouthome.
41. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30(6):473-483.
42. Goodwin P.J., Black J.T., Bordeleau L.J., Ganz P.A. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J. Natl. Cancer Inst. 2003, 95(4):263-281.
43. Kosinski M., Keller S.D., Hatoum H.T., Kong S.X., Ware J.E. The SF-36 health survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med. Care 1999, 37(5 Suppl.):MS10-MS22.
44. Ware J.E., Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J. Clin. Epidemiol. 1998, 51(11):903-912.
45. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 2010, 61:301-316.
46. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 2009, 115(2):86-96.
47. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
48. Renehan A.G., Roberts D.L., Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 2008, 114(1):71-83.
49. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 2004, 92(3):347-355.
50. Rose D.P., Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2014, 40(1):1-12.
51. Howe L.R., Subbaramaiah K., Hudis C.A., Dannenberg A.J. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 2013, 19(22):6074-6083.
52. Cummings S.R., Tice J.A., Bauer S., et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J. Natl. Cancer Inst. 2009, 101(6):384-398.
53. Goodwin P.J., Ennis M., Pritchard K.I., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 2002, 20(1):42-51.
54. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94(8):606-616.
55. Pierce B.L., Ballard-Barbash R., Bernstein L., et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 2009, 27(21):3437-3444.
56. Diggle P.J., Liang K.-Y., Zeger S.L. Analysis of Longitudinal Data 2002, Oxford University Press, Second ed.
57. Verbeke G., Fieuws S., Molenberghs G., Davidian M. The analysis of multivariate longitudinal data: a review. Stat. Methods Med. Res. 2014, 23(1):42-59.
58. Jensen S.M., Pipper C.B., Ritz C. Evaluation of multi-outcome longitudinal studies. Stat. Med. 2015, 34(12):1993-2003.
59. Pierce J.P., Natarajan L., Caan B.J., et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007, 298(3):289-298.
60. Rock C.L., Flatt S.W., Sherwood N.E., Karanja N., Pakiz B., Thomson C.A. Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial. JAMA 2010, 304(16):1803-1810.
61. Collaborative Institutional Training Initiative at the University of Miami. (Accessed August, 25, 2015). https://www.citiprogram.org/.
62. Kasenda B., von Elm E., You J., et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 2014, 311(10):1045-1051.
63. Kasenda B., von Elm E.B., You J., et al. Learning from failure-rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med. Res. Methodol. 2012, 12:131.
64. Nasser N., Grady D., Balke C.W. Commentary: Improving participant recruitment in clinical and translational research. Acad. Med. 2011, 86(11):1334-1335.
65. Snyder D.C., Morey M.C., Sloane R., et al. Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. Psycho-Oncology 2009, 18(4):429-439.
66. Patterson R.E., Colditz G.A., Hu F.B., et al. The 2011-2016 transdisciplinary research on energetics and cancer (TREC) initiative: rationale and design. Cancer Causes Control 2013, 24(4):695-704.